"The Company just reached a milestone in its vision of providing what it believes to be a highly accurate field instrument that, subject to applicable regulatory approval, may provide lung disease testing worldwide. Today's news is exciting because it accelerates the development process of the BreathTest-1000 and we believe gets us closer to joining the front-line in the fight against lung diseases, such as COVID-19," stated Thomas B. Pickens III, Chairman and Chief Executive Officer of
"The Company was able to move quickly in the development of the BreathTest-1000(TM) because the core mass spectrometry technology it utlizes has been fully commercialized and deployed for explosives trace detection. Our goal is to satisfy all regulatory requirements for the BreathTest-1000 as rapidly as possible once the necessary application developments are completed. We believe that few, if any, changes will need to be made to the underlying technology. We plan to devote our efforts towards developing a simple and consistent sample introduction system,"
About
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, whether we can successfully develop our proprietary technologies and whether the market will accept our products and services, as well as other risk factors and business considerations described in the Company's
Company Contact:
.
(C) 2020 M2 COMMUNICATIONS, source